Assembly Biosciences Files 8-K on Material Agreement
Ticker: ASMB · Form: 8-K · Filed: Jan 3, 2025 · CIK: 1426800
| Field | Detail |
|---|---|
| Company | Assembly Biosciences, INC. (ASMB) |
| Form Type | 8-K |
| Filed Date | Jan 3, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $64,944.75, $67,142.88, $69,540.84, $71,938.80 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, 8-k
Related Tickers: ASMB
TL;DR
ASMB filed an 8-K on Dec 30, 2024, for a material agreement & financial obligation. Watch for details.
AI Summary
Assembly Biosciences, Inc. filed an 8-K on January 3, 2025, reporting a material definitive agreement and a direct financial obligation entered into on December 30, 2024. The filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant new contractual obligations or financial arrangements for Assembly Biosciences, Inc., which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing of a material definitive agreement and financial obligation suggests significant business developments that could carry financial risks or opportunities.
Key Players & Entities
- Assembly Biosciences, Inc. (company) — Registrant
- December 30, 2024 (date) — Date of earliest event reported
- January 3, 2025 (date) — Filing date
FAQ
What type of material definitive agreement was entered into by Assembly Biosciences, Inc. on December 30, 2024?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on December 30, 2024.
What is the nature of the direct financial obligation or off-balance sheet arrangement reported?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specific details are not provided in the summary information.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 30, 2024.
What is the SEC file number for Assembly Biosciences, Inc.?
The SEC file number for Assembly Biosciences, Inc. is 001-35005.
What is the principal executive office address for Assembly Biosciences, Inc.?
The principal executive offices are located at Two Tower Place, 7th Floor, South San Francisco, California 94080.
Filing Stats: 675 words · 3 min read · ~2 pages · Grade level 10.5 · Accepted 2025-01-03 16:05:11
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 ASMB The Nasdaq Global Select Marke
- $64,944.75 — January 1, 2025 – December 31, 2025 $64,944.75* January 1, 2026 – December 31, 2026
- $67,142.88 — January 1, 2026 – December 31, 2026 $67,142.88 January 1, 2027 – December 31, 2027
- $69,540.84 — January 1, 2027 – December 31, 2027 $69,540.84 January 1, 2028 – December 31, 2028
- $71,938.80 — January 1, 2028 – December 31, 2028 $71,938.80 January 1, 2029 – December 31, 2029
- $74,536.59 — January 1, 2029 – December 31, 2029 $74,536.59 _______________ * Subject to an aba
Filing Documents
- asmb-20241230.htm (8-K) — 54KB
- asmb-ex10_1.htm (EX-10.1) — 45KB
- img33231229_0.jpg (GRAPHIC) — 114KB
- 0000950170-25-001141.txt ( ) — 384KB
- asmb-20241230.xsd (EX-101.SCH) — 31KB
- asmb-20241230_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On December 30, 2024, Assembly Biosciences, Inc. (the "Company") and Arsenal Biosciences, Inc. (the "Sublessor") entered into a First Amendment to Sublease to amend the Company's sublease of approximately 20,000 square feet of office and laboratory space (the "Premises") located at 2 Tower Place, 7th Floor, South San Francisco, California (the "Amendment"). The Amendment extends the term of the sublease through September 30, 2029. Under the terms of the Amendment, the Company is obligated to pay the Sublessor base rent of the following amounts: Months Total Monthly Base Rent January 1, 2025 – December 31, 2025 $64,944.75* January 1, 2026 – December 31, 2026 $67,142.88 January 1, 2027 – December 31, 2027 $69,540.84 January 1, 2028 – December 31, 2028 $71,938.80 January 1, 2029 – December 31, 2029 $74,536.59 _______________ * Subject to an abatement of one month's base rent. The Company also has a right of first refusal under the terms of the Amendment to sublease additional space leased by Sublessor on the 6th floor of the building. The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which the Company, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information under Item 1.01 above is incorporated by reference into this Item 2.03, and is qualified in its entirety by reference to the full text of the Sublease, a copy of which is attached hereto as Exhibit 10.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 10.1 First Amendment to Sublease, dated December 30, 2024, by and between Arsenal Biosciences, Inc. and Assembly Biosciences, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Assembly Biosciences, Inc. Date: January 3, 2025 By: /s/ John O. Gunderson John O. Gunderson VP, General Counsel and Corporate Secretary 2